ImmunoSensation - the immune sensory system

Curr Med Res Opin . 2022 Sep 28

Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP

Johannes Oldenburg, Steven W Pipe, Maria Elisa Mancuso, Robert Klamroth, Abel Hassoun, Martin Olivieri, Georg Goldmann, Gili Kenet, Wolfgang Miesbach, Jolana Schmiedl, Inga Hegemann

Objective: Prophylaxis treatment is the current standard of care for patients with severe hemophilia. Factor concentrates with improved pharmacokinetics have offered more options for individualizing treatment. The treatment focus may be on increased protection, aiming for higher trough factor levels or longer dosing intervals to reduce the burden of hemophilia. Both aspects can have long-term effects on joint health. Products, such as rVIII‑SingleChain and rIX-FP have been developed to reduce the treatment burden for patients with hemophilia and optimize prophylactic efficacy. The objective of this report is to provide a summary of the clinical experience of different Hemophilia Treatment Centers in managing the switch to rVIII-SingleChain or rIX-FP in patients with hemophilia.

PMID: 36170120